<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Gastric acid control is important for treatment of <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e> associated with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Substantial indirect evidence suggests that gastric acid control may have a chemopreventive role in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>AIM: To compare the pharmacodynamic efficacy of <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> and <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> at two dosages for intragastric pH control with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> received open-label consecutive treatment (a 15-day period of once-daily dosing followed by a 10-day period of twice-daily dosing) with <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> (40-mg capsules) and <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> (30-mg capsules) in random order with no washouts </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty-four-hour intragastric pH was recorded on the last day of each dosing period </plain></SENT>
<SENT sid="5" pm="."><plain>The primary end point was the percentage of time with intragastric pH &gt; 4.0 </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: In the per-protocol once- (n = 46) and twice-daily (n = 41) analyses, the percentage of time with intragastric pH &gt; 4.0 was significantly (P &lt; 0.0001) longer after once- (67.1%) or twice-daily (81.2%) <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> than after once- (50.8%) or twice-daily (64.3%) <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>The proportion of patients with intragastric pH &gt; 4.0 for &gt;12 h was significantly higher for <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> than <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> with once- (P = 0.004) and twice-daily (P = 0.016) dosing </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="50275">Esomeprazole</z:chebi> 40 mg is significantly more effective than <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> 30 mg in controlling intragastric pH with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
</text></document>